All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Lymphoma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View lymphoma & CLL content recommended for you

SOHO 2022

Share:

Sep 28, 2022

X post image

7 Dec 2022

What are the current and future strategies in the disease management of elderly patients with aggressive B-cell #lymphoma, presented at #SOHO22. Read more here 👉 https://t.co/S5hebt8t65. #lymsm

X post image

14 Nov 2022

The use of CNS prophylaxis and CNS-IPI in patients with DLBCL was highlighted at #SOHO22. Read more here 👉 https://t.co/ITLDjqI2X4. #lymphoma #lymsm

X post image

5 Oct 2022

📽️ During #SOHO22, the Lymphoma Hub spoke with
Professor Catherine Thieblemont and we asked, How can we improve care for elderly patients with aggressive #lymphoma? #lymsm
Here what she had to say: https://t.co/j8tMBvjTJK.

X post image

30 Sept 2022

Congress | #SOHO22 Alex Herrera from @cityofhope presents updated results from a phase II study where camidanlumab tesirine demonstrated an ORR of 70.1%, median DOR of 13.7 months and median PFS of 9.1 months in patients with R/R CHL #Lymphoma #lymsm

X post image

30 Sept 2022

Congress | #SOHO22 Alex Herrera from @cityofhope discusses the treatment of patients with Hodgkin #Lymphoma after brentuximab vedotin and Anti-PD1 failure #lymsm #medicalcongress

X post image

30 Sept 2022

Congress | #SOHO22 Alison Moskowitz from @MSKCancerCenter delivers an interesting talk on the novel agents brentuximab vedotin, nivolumab, and pembrolizumab, and how their introduction has changed the management of Hodgkin #Lymphoma #lymsm #medicalcongress

X post image

30 Sept 2022

Congress | #SOHO22 @jonathonbcohen from @WinshipAtEmory shares updated results from the ongoing BRUIN study. Pirtobrutinib demonstrates efficacy in pretreated, poor-prognosis patients with mantle cell #Lymphoma following multiple prior lines of therapy #lymsm #medicalcongress

X post image

30 Sept 2022

Congress | #SOHO22 Jia Ruan from @WeillCornell talks about numerous studies ongoing to evaluate novel agents, and how the advancement of BTK inhibitors and other targeted agents to earlier lines of treatment is reshaping the landscape for mantle cell #lymphoma #lymsm

X post image

30 Sept 2022

Congress | #SOHO22 @jonathonbcohen from @WinshipAtEmory discusses immunotherapeutic approaches for patients with mantle cell #Lymphoma and the need to evaluate combination therapies that incorporate BTK inhibitors and other targeted agents with immunotherapies #lymsm

X post image

30 Sept 2022

Congress | #SOHO22 @LymphClinician from @Umich talks about targeted agents with demonstrated efficacy in patients with R/R mantle cell #lymphoma which are being explored in frontline therapy. #lymsm

X post image

30 Sept 2022

Congress | #SOHO22 @AndreGoyMD from @HMHNewJersey discusses the progress in novel therapies and routine diagnostics, and the development of new treatment strategies for mantle cell #lymphoma, no longer based on dose intensity/age dichotomy #lymsm

X post image

30 Sept 2022

Congress | #SOHO22 John Burke, Rocky Mountain Cancer Center, showed results from a cost-effectiveness analysis of Pola-R-CHP vs R-CHOP in front-line treatment of diffuse large B-cell #Lymphoma reinforcing the clinical findings from the POLARIX study #lymsm

X post image

30 Sept 2022

Congress | #SOHO22 @ChrisRFlowersMD @MDAndersonNews presented results from the phase III #POLARIX study. Pola-R-CHP showed a 27% reduction in relative risk of progression, relapse, or death, and a similar safety profile compared to R-CHOP in untreated patients with DLBCL #lymsm

X post image

30 Sept 2022

Congress | #SOHO22 @c_thieblemont from @HopSaintLouis delivers a fascinating presentation on the management options for elderly patients with aggressive B-cell in first-, second-, and third-line therapies, highlighting key results from several recent studies #Lymphoma #lymsm

X post image

30 Sept 2022

Congress | #SOHO22 Dr. Victor Orellana-Noia from @WinshipAtEmory presented results from retrospective analyses of CNS prophylaxis recipients with DLBCL. They highlight the lack of randomized phase III studies, and the potential role ctDNA may play #Lymphoma #lymsm

X post image

30 Sept 2022

Congress | #SOHO22 @GregNowakowski from @MayoClinic @MayocancerCare talks about treatment options for aggressive B-cell #Lymphoma Post CAR T-cell therapy #lymsm

X post image

30 Sept 2022

Congress | #SOHO22 @mike_dickinson1 from @PeterMacCC discusses the potential of bispecific antibodies, as a monotherapy and as a combination in earlier lines of therapy and as a salvage following CAR-T therapy in aggressive B-cell #Lymphoma #lymsm

X post image

30 Sept 2022

Congress | #SOHO22 @mana1981 from @CUAnschutz discusses when to choose CAR T-cell therapy vs ASCT in relapsed/refractory aggressive B-cell #Lymphoma They discuss results from the ZUMA 7, TRANSFORM, and BELINDA trials #lymsm #medicalcongress

X post image

30 Sept 2022

Congress | #SOHO22 @DrJFriedberg from @UofR asks whether RCHP-polatuzumab to replace RCHOP as the preferred upfront treatment in intermediate and high clinical risk subsets of diffuse large B-cell #lymphoma
They highlight the POLARIX trial #lymsm

X post image

30 Sept 2022

Congress | #SOHO22 Sattva Neelapu from @MDAndersonNews delivers a fascinating talk on the future directions of CAR-T in #Lymphoma including targets, resistance, persistence, and ways to improve CAR-T #lysm #medicancongress

X post image

30 Sept 2022

CONGRESS| #SOHO22 @LNastoupilMD, @MDAndersonNews Phase II expansion study results of mosunetuzumab monotherapy demonstrates high efficacy (CR:60%, p<0.001; ORR:80%) and a manageable safety profile in patients with R/R #FL, who have received ≥ 2 prior lines of therapy.

X post image

30 Sept 2022

CONGRESS| #SOHO22 Dr. Prashant Kapoor, @MayoClinic discusses how the genomic landscape of WM, primarily the CXCR4 and MYD88 genotypes, predict clinical features of the disease, and guide treatment options for patients within the frontline and R/R setting #lymsm

X post image

30 Sept 2022

CONGRESS| #SOHO22 @MediHumdani, @MedicalCollege discusses whether there is still a role for transplantation in the management of #FL, in an era of #CAR T-cell therapy #lymphoma #lymsm #medicalcongress

X post image

30 Sept 2022

CONGRESS| #SOHO22 @LNastoupilMD, @MDAndersonNews gives a talk on how to choose the best sequence of treatments for optimal effect in patients with indolent #lymphoma, in both the frontline and R/R settings. #lymsm #medicalcongress

X post image

30 Sept 2022

CONGRESS| #SOHO22
Tania Dexter from the Royal Marsden hospital presents data confirming the correlation between clonal TRBC1 status by flow cytometry and T-cell clonality by molecular testing. #lymphoma #lymsm #medicalcongress

X post image

30 Sept 2022

CONGRESS| #SOHO22
Won Seog Kim, Samsung Medical Center (@SKKGSB) gives an overview of the treatment advances in NK/T cell lymphoma. #lymphoma #lymsm #medicalcongress

X post image

30 Sept 2022

CONGRESS| #SOHO22 @PamAllenMD1, @WinshipAtEmory talks about how to optimally incorporate different novel agents in the clinical management of #CTCL. #lymphoma #lymsm #medicalcongress

X post image

30 Sept 2022

CONGRESS| #SOHO22 Dr. Matthew Lunning (@lymphomaphilia), @NebraskaMed @UNMC discusses the novel treatment agents for patients with R/R #PTCL. #lymphoma #lymsm #medicalcongress

X post image

30 Sept 2022

CONGRESS| #SOHO22 @NehaMehtaShahMD, @WUSTLmed discusses therapeutic regimens on the horizon for improving treatment outcomes in newly diagnosed patients with #PTCL, including variations of CHOP-based therapy #lymphoma #lymsm #medicalcongress

X post image

30 Sept 2022

CONGRESS| #SOHO22 @FVega957, @MDAndersonNews shares insights on how molecular advancements can lead to better diagnosis and treatments in #PTCL #lymphoma #lymsm #medicalcongress

X post image

30 Sept 2022

Keep an eye on our Twitter page for live coverage! #SOHO22📲

Sessions covered today:

SESSION VIII: T-CELL LYMPHOMA

SESSION IX: INDOLENT B-CELL

LYMPHOMA PLENARY SESSION III

SESSION X: AGGRESSIVE B-CELL LYMPHOMA

SESSION XI: MANTLE CELL LYMPHOMA

SESSION XII: HODGKIN LYMPHOMA

X post image

29 Sept 2022

CONGRESS|#SOHO22|Poster
Jacqueline Barrientos, @ZuckerSoM Real world data from informCLL showed treatment patterns and rates of prognostic testing in black patients vs general population with #CLL,highlighting the need for close monitoring of disease status in these pts #lymsm

X post image

29 Sept 2022

CONGRESS| #SOHO22 Dr Clare Sun, @TheBethesdaLabs discusses the available supportive therapies in patients with #CLL who are immunocompromised, including the use of growth factor support, infection prophylaxis, vaccinations, and immunoglobulin replacement. #lymphoma #leusm

X post image

29 Sept 2022

CONGRESS| #SOHO22
Prof F Cymbalista shares real world studies of small molecule therapy in patients with #CLL, highlighting data for ibrutinib and venetoclax #lymphoma #leusm #medicalcongress

X post image

29 Sept 2022

CONGRESS| #SOHO22 @anthonymatomd, @MSKCancerCenter presents an interesting debate on why sequential use of small molecule targeted therapies are the way to go for patients with #CLL. #lymphoma #lymsm #leusm #medicalcongress

X post image

29 Sept 2022

CONGRESS| #SOHO22 Jennifer R. Brown from @DanaFarber presents an interesting debate in favor of combination over sequential use of small molecule targeted therapies in patients with #CLL. #lymphoma #leusm #medicalcongress

X post image

29 Sept 2022

CONGRESS| #SOHO22
Dr. John C. Byrd, @OSUWexMed presents a comparative analysis of the current covalent BTK inhibitors for #CLL. #lymphoma #leusm #medicalcongress

X post image

29 Sept 2022

CONGRESS| #SOHO22 Dr. Kostas Stamatopoulos, @CERTHellas discusses the clinical significance of stratifying patients with #CLL into distinct stereotyped subsets, with emphasis on subset#2. #leusm #lymsm #medicalcongress

X post image

29 Sept 2022

CONGRESS|#SOHO22|Poster
Ryan Jacobs, @LevineCancer, real-world adherence comparison for ibrutinib vs acalabrutinib monotherapy shows that first line once-daily ibrutinib has a higher treatment adherence than first line twice-daily acalabrutinib in patients with #CLL/#SLL

X post image

29 Sept 2022

CONGRESS| #SOHO22 |Poster Jennifer Woyach, @OSUCCC_James, 5-year analysis from RESONATE-2 study showed ibrutinib's continued benefit over time as a first-line treatment in patients with #CLL/#SLL, with improved CR rates and decreased prevalence of adverse events #leusm

X post image

29 Sept 2022

CONGRESS | #SOHO22 Dr.Thomas Kipps, @UCSDCancer discusses the challenge of addressing the resistance to targeted therapies in #CLL, using the prime example of BTK inhibitors. #lymphoma #lymsm #leusm #medicalcongress

X post image

29 Sept 2022

The @lymphomahub will be virtually covering the following sessions today:

PLENARY SESSION II

SESSION VII: CHRONIC LYMPHOCYTIC LEUKEMIA

Stay tuned for live updates, key insights, and interview coverage!

#SOHO22 #medicalcongress #cancerawareness #hematology #lymsm

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

SOHO 2022 Society of Hematologic Oncology

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?

Newsletter

Subscribe to get the best content delivered to your inbox